Computational Pathology for Accurate Prediction of Breast Cancer Recurrence: Development and Validation of a Deep Learning–Based Tool
- 16 July 2025
- journal article
- Published by Elsevier in Laboratory Investigation
- Vol. 38 (12) , 100847
Abstract
No abstract availableKeywords
Funding Information
- National Institute of Biomedical Imaging and Bioengineering (GR125886)
- National Institutes of Health
- Alliance for Clinical Trials in Oncology Foundation
- Foundation for the National Institutes of Health (R01 CA276301)
- Foundation for the National Institutes of Health (R21 CA273665)
- Foundation for the National Institutes of Health (R21 EB029493)
- National Cancer Institute (R21 EB029493)
- National Cancer Institute (R01 CA276301)
This publication has 40 references indexed in Scilit:
- PHIM-MIL: Multiple instance learning with prototype similarity-guided feature fusion and hard instance mining for whole slide image classificationInformation Fusion, 2024
- Attention2Minority: A salient instance inference-based multiple instance learning for classifying small lesions in whole slide imagesComputers in Biology and Medicine, 2023
- Association of Social Determinants and Tumor Biology With Racial Disparity in Survival From Early-Stage, Hormone-Dependent Breast CancerJAMA Oncology, 2023
- Pan-cancer integrative histology-genomic analysis via multimodal deep learningCancer Cell, 2022
- Artificial intelligence predicts immune and inflammatory gene signatures directly from hepatocellular carcinoma histologyJournal of Hepatology, 2022
- Prediction of HER2-positive breast cancer recurrence and metastasis risk from histopathological images and clinical information via multimodal deep learningComputational and Structural Biotechnology Journal, 2021
- Racial and ethnic disparities in 21-gene recurrence scores, chemotherapy, and survival among women with hormone receptor-positive, node-negative breast cancerBreast Cancer Research and Treatment, 2020
- Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine TherapyJAMA Oncology, 2020
- Nomogram update based on TAILORx clinical trial results - Oncotype DX breast cancer recurrence score can be predicted using clinicopathologic dataThe Breast, 2019
- Low utility of Oncotype DX® in the clinicCancer Medicine, 2017